JBPOS0552

JBPOS0552 is a preclinical-stage small molecule candidate developed by Bio-Pharm Solutions for the treatment of neurological disorders, including epilepsy, infantile spasms (IS), and Lennox-Gastaut syndrome (LGS), as well as for pain management. The compound has been included in the NIH National Institute of Neurological Disorders and Stroke (NINDS) Anticonvulsant Screening Program (ASP), often referred to as the 'Red Book' program, which evaluates potential anticonvulsant compounds. While the specific molecular target for JBPOS0552 is not explicitly detailed in public pipeline summaries, Bio-Pharm Solutions specializes in the development of ligands targeting metabotropic glutamate receptors (mGluRs) for central nervous system indications, suggesting a similar mechanism of action to its lead candidate, JBPOS0101.